GleamWall
中文EN

GNLX GENELUX Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1231457 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-95.3%
TTM net income YoY-5.6%
TTM EPS YoY18.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-396,200.0%
Net margin-373,362.5%
FCF margin-270,112.5%
EBITDA margin-393,262.5%

Returns

ROE-130.6%
ROA-95.4%
ROIC (approx.)-180.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue4,762.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$8,000$8,000
R&D expense$19.85M$19.00M
SG&A expense$13.37M$12.71M
Operating income-$33.21M-$31.70M
Net income-$32.15M-$29.87M
EBITDA-$32.97M-$31.46M
EPS (basic)-0.86-0.95
EPS (diluted)-0.86-0.95
Weighted avg. shares (diluted)37.18M31.45M
Balance sheet
Cash & equivalents$5.33M$8.56M
Short-term investments—$22.33M
Current assets$15.13M$31.55M
PP&E, net$2.17M$1.32M
Total assets$19.03M$34.72M
Current liabilities$6.22M$6.90M
Total liabilities$7.48M$8.44M
Shareholders' equity$11.54M$26.27M
Shares outstanding38.14M34.73M
Cash flow statement
Operating cash flow-$25.27M-$21.23M
Capital expenditure$1.10M$381,000
Free cash flow-$26.37M-$21.61M
Investing cash flow$12.14M-$8.13M
Financing cash flow$9.89M$28.51M
Depreciation & amortization$244,000$235,000
Stock-based compensation$5.87M$5.74M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.